.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Citi
Express Scripts
Federal Trade Commission
McKinsey
QuintilesIMS
McKesson
Moodys
Medtronic
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Novartis Pharms Corp Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?

NOVARTIS PHARMS CORP has sixty-eight approved drugs.

There are one hundred and twenty US patents protecting NOVARTIS PHARMS CORP drugs and there have been six Paragraph IV challenges on NOVARTIS PHARMS CORP drugs in the past three years.

There are one thousand eight hundred and fifty-nine patent family members on NOVARTIS PHARMS CORP drugs in seventy-three countries and one hundred and sixty-five supplementary protection certificates in fifteen countries.

Summary for Novartis Pharms Corp

International Patents:1859
US Patents:120
Tradenames:58
Ingredients:49
NDAs:68
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-002May 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-002May 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-001Nov 20, 2008RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-005Nov 16, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpMOXEZAmoxifloxacin hydrochlorideSOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010AT2RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-005Nov 16, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpTOBRADEXdexamethasone; tobramycinOINTMENT;OPHTHALMIC050616-001Sep 28, 1988RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpKISQALIribociclib succinateTABLET;ORAL209092-001Mar 13, 2017RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014► Subscribe► Subscribe
Novartis Pharms CorpCILOXANciprofloxacin hydrochlorideOINTMENT;OPHTHALMIC020369-001Mar 30, 1998► Subscribe► Subscribe
Novartis Pharms CorpTRAVATAN ZtravoprostSOLUTION/DROPS;OPHTHALMIC021994-001Sep 21, 2006► Subscribe► Subscribe
Novartis Pharms CorpVIGAMOXmoxifloxacin hydrochlorideSOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003► Subscribe► Subscribe
Novartis Pharms CorpZOFRANondansetron hydrochlorideINJECTABLE;INJECTION020007-001Jan 4, 1991► Subscribe► Subscribe
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007► Subscribe► Subscribe
Novartis Pharms CorpCIPRO HCciprofloxacin hydrochloride; hydrocortisoneSUSPENSION/DROPS;OTIC020805-001Feb 10, 1998► Subscribe► Subscribe
Novartis Pharms CorpZOFRAN ODTondansetronTABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 1999► Subscribe► Subscribe
Novartis Pharms CorpZOFRANondansetron hydrochlorideTABLET;ORAL020103-003Aug 27, 1999► Subscribe► Subscribe
Novartis Pharms CorpXTOROfinafloxacinSUSPENSION/DROPS;OTIC206307-001Dec 17, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for NOVARTIS PHARMS CORP drugs

Drugname Dosage Strength Tradename Submissiondate
deferasiroxTablets180 mgJADENU4/28/2016
travoprostOphthalmic Solution0.003%IZBA12/30/2015
nepafenacOphthalmic Suspension0.3%ILEVRO12/21/2015
deferasiroxTablets180 mgJADENU10/23/2015
deferasiroxTablets90 mg and 360 mgJADENU10/19/2015
olopatadine hydrochlorideOphthalmic Solution0.7%PAZEO9/10/2015
difluprednateOphthalmic Emulsion0.05%DUREZOL5/1/2014
eltrombopag olamineTablets12.5 mg and 25 mgPROMACTA2/4/2014
eltrombopag olamineTablets50 mg and 75 mgPROMACTA1/7/2014
ciprofloxacin and dexamethasoneOtic Suspension0.3%/0.1%CIPRODEX7/31/2012
moxifloxacin hydrochlorideOphthalmic Solution10.5%MOXEZA2/29/2012
argatroban in sodium chlorideInjection1 mg/mL, 50 mL vialsARGATROBAN12/16/2011
lapatinib ditosylateTablets250 mgTYKERB3/14/2011
olopatadine hydrochlorideNasal Spray0.665 mg/ SprayPATANASE6/29/2009
travoprost (preserved)Ophthalmic Solution0.00%TRAVATAN Z2/19/2009
olopatadine hydrochlorideOphthalmic Solution0.20%PATADAY9/8/2008
argatrobanInjection100 mg/mL, 2.5 mL vialsARGATROBAN9/24/2007
olopatadine hydrochlorideOphthalmic Solution0.10%PATANOL7/17/2006
moxifloxacin hydrochlorideOphthalmic0.50%VIGAMOX12/22/2005
ondansetron hydrochlorideOral Solution4 mg/5 mLZOFRAN12/20/2004

Non-Orange Book Patents for Novartis Pharms Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,439,342Thrombopoietin mimetics► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
7,820,8192,4-pyrimidinediamine compounds and their uses► Subscribe
7,060,827Intermediates useful for making 2,4-pyrimidinediamine compounds► Subscribe
6,838,449 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
7,674,887Thrombopoietin mimetics► Subscribe
7,709,012Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
7,939,625Somatostatin analogues► Subscribe
9,035,021Somatostatin analogues► Subscribe
7,812,029Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Corp Drugs

Country Document Number Estimated Expiration
China100542530► Subscribe
Colombia6781544► Subscribe
Cyprus1107253► Subscribe
Hong Kong1059573► Subscribe
South Korea20120028390► Subscribe
Taiwan200843742► Subscribe
European Patent Office3045164► Subscribe
China101616895► Subscribe
Australia2011343775► Subscribe
Norway20030484► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00055Denmark► SubscribePRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
2004012Lithuania► SubscribePRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C0086France► SubscribePRODUCT NAME: PANOBINOSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1023 20150901
7 5020-2015Slovakia► SubscribePRODUCT NAME: CERITINIB; REGISTRATION NO/DATE: EU/1/15/999 20150508
2016003Lithuania► SubscribePRODUCT NAME: PANOBINOSTATAS; REGISTRATION NO/DATE: EU/1/15/1023 20120828
2012017Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
2015 00017Denmark► SubscribePRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
90027-0Sweden► SubscribePRODUCT NAME: TRAVOPROST
/2007Austria► SubscribePRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070822
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
QuintilesIMS
Teva
Johnson and Johnson
Novartis
Boehringer Ingelheim
Fish and Richardson
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot